Draft Genome Sequence of Bacillus velezensis Strain Marseille-Q1230, Isolated from a Stool Sample from a Severely Malnourished Child

Konaté, Salimata; Zgheib, Rita; Camara, Aminata; Doumbo, Ogobara K.; Djimdé, Abdoulaye; Koné, Abdoulaye K.; Théra, Mahamadou A.; Fournier, Pierre‐Edouard; Alou, Maryam Tidjani; Raoult, Didier; Million, Matthieu

doi:10.1128/mra.00514-21

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One paper (D'Agostin et al., 2021) reviewed human case reports related to probiotic intake of B. clausii which were already discussed in previous EFSA statements. Four papers had methodology problems related to the identification methodology used (Garcia et al., 2021 ; Severiche‐Bueno et al., 2021 ; Lampropoulos et al., 2021 ) and/or the source attribution (Konate et al., 2021 ; Severiche‐Bueno et al., 2021). Three papers described predisposing factors for the infection (Garcia et al., 2021; Konate et al., 2021; Lampropoulos et al., 2021).…”

Section: Assessmentmentioning

confidence: 99%

Update of the list of QPS‐recommended microbiological agents intentionally added to food or feed as notified to EFSA 16: suitability of taxonomic units notified to EFSA until March 2022

Koutsoumanis¹,

Allende²,

Álvarez‐Ordóñez³

et al. 2022

EFS2

View full text Add to dashboard Cite

The qualified presumption of safety (QPS) approach was developed to provide a regularly updated generic pre‐evaluation of the safety of microorganisms, intended for use in the food or feed chains, to support the work of EFSA's Scientific Panels. The QPS approach is based on an assessment of published data for each agent, with respect to its taxonomic identity, the body of relevant knowledge, safety concerns and occurrence of antimicrobial resistance. Safety concerns identified for a taxonomic unit (TU) are, where possible, confirmed at the species/strain or product level and reflected by ‘qualifications’. In the period covered by this statement, no new information was found that would change the status of previously recommended QPS TUs. Of the 50 microorganisms notified to EFSA in October 2021 to March 2022 (inclusive), 41 were not evaluated: 10 filamentous fungi, 1 Enterococcus faecium , 1 Clostridium butyricum, 3 Escherichia coli and 1 Streptomyces spp. because are excluded from QPS evaluation, and 25 TUs that have already a QPS status. Nine notifications, corresponding to seven TUs were evaluated: four of these, Streptococcus salivarius, Companilactobacillus formosensis, Pseudonocardia autotrophica and Papiliotrema terrestris , being evaluated for the first time. The other three, Microbacterium foliorum, Pseudomonas fluorescens and Ensifer adhaerens were re‐assessed. None of these TUs were recommended for QPS status: Ensifer adhaerens, Microbacterium foliorum, Companilactobacillus formosensis and Papiliotrema terrestris due to a limited body of knowledge , Streptococcus salivarius due to its ability to cause bacteraemia and systemic infection that results in a variety of morbidities, Pseudonocardia autotrophica due to lack of body of knowledge and uncertainty on the safety of biologically active compounds which can be produced, and Pseudomonas fluorescens due to possible safety concerns .

show abstract

Section: Assessmentmentioning

confidence: 99%

Update of the list of QPS‐recommended microbiological agents intentionally added to food or feed as notified to EFSA 16: suitability of taxonomic units notified to EFSA until March 2022

Koutsoumanis¹,

Allende²,

Álvarez‐Ordóñez³

et al. 2022

EFS2

View full text Add to dashboard Cite

show abstract

“…Importantly, several B. velezensis strains (e.g., strains LOH112, ADS024, Marseille-Q1230, MV4, and MV11) have been isolated from human stool and cervicovaginal samples, suggesting that B. velezensis naturally occurs in the human gut and vaginal microbiotas [ 57 , 58 , 59 , 60 ]. B. velezensis strains secrete a wide array of bioactive molecules, including antimicrobial metabolites such as macrolactin, antimicrobial lipopeptides like fengycin, and digestive enzymes [ 61 ].…”

Section: Introductionmentioning

confidence: 99%

Genetic and Phenotypic Characterization of Bacillus velezensis Strain BV379 for Human Probiotic Applications

Brutscher,

Gebrechristos,

Garvey

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Bacterial spore-forming Bacillaceae species, including Bacillus subtilis and Heyndrickxia coagulans, are increasingly utilized for probiotic dietary supplementation. Bacillus velezensis is a Bacillus species that is frequently used as a direct-fed microbial in animal feed but less so as a probiotic for humans. The objective of this study was to characterize the suitability of the Bacillus velezensis strain BV379 for probiotic applications by (1) in silico screening for both adverse genetic elements and putatively beneficial traits, (2) in vitro evaluation of interactions with human intestinal epithelial cells, and (3) in vitro characterization of BV379 spore viability at various temperatures, pH, and in the presence of bile salt. In silico screening of the BV379 genome revealed few genes encoding Bacillaceae-associated toxins, virulence factors, and enzymes involved in the production of toxins. While BV379 encodes five antimicrobial resistance genes, minimum inhibitory concentration assays determined that BV379 is susceptible to all eight clinically relevant antibiotics tested. Preliminary cell culture experiments showed that BV379 lysates did not adversely impact human intestinal epithelial cell viability and monolayer permeability. It was also determined that BV379 spores can easily tolerate the harsh pH, bile salt, and microaerobic conditions typical of the GI tract. Altogether, the results presented herein support the safety and potential of Bacillus velezensis strain BV379 for use as an oral probiotic.

show abstract

Antibiotic susceptibility of Bacillus velezensis

Heo

Kong

Kim

et al. 2022

FEMS Microbiology Letters

View full text Add to dashboard Cite

We evaluated the antibiotic minimum inhibitory concentrations (MICs) of 123 Bacillus velezensis strains predominantly isolated from fermented soybean foods from Korea. When the 2018 European Food Safety Authority breakpoint values for Bacillus spp. were applied, all the strains were sensitive to chloramphenicol, clindamycin, erythromycin, gentamicin, kanamycin, tetracycline, and vancomycin, and eight strains (6.5%) were resistant to streptomycin. The population distribution in MIC tests with streptomycin was continuous and the profile was clearly different from that expected for acquired antibiotic resistance. As of October 25th 2021, there were 181 complete published genomes of B. velezensis strains; 175 (96.7%) and 136 (75.2%) of these strains respectively possess potential tetracycline and streptomycin resistance genes tetL and ant(6) in the chromosome. In B. licheniformis, SpeG confers resistance to clindamycin and there is an ‘speG’ gene annotated in the genomes of 180 B. velezensis strains; however, the gene products exhibit ≤ 26.6% amino acid identity with that from B. licheniformis DSM 13T. All the potential antibiotic resistance genes in the 181 B. velezensis strains were intrinsic, and traits of lateral gene transfer were not found. In this context, B. velezensis may not present a high risk in terms of antibiotic resistance in food fermentation or human use.

show abstract

Draft Genome Sequence of Bacillus velezensis Strain Marseille-Q1230, Isolated from a Stool Sample from a Severely Malnourished Child

Abstract: Bacillus velezensis , a species first described in 2005, has been mostly associated with plants and the environment. To date, there is no genome available for this species from human samples.

Cited by 4 publications

References 22 publications

Update of the list of QPS‐recommended microbiological agents intentionally added to food or feed as notified to EFSA 16: suitability of taxonomic units notified to EFSA until March 2022

Update of the list of QPS‐recommended microbiological agents intentionally added to food or feed as notified to EFSA 16: suitability of taxonomic units notified to EFSA until March 2022

Genetic and Phenotypic Characterization of Bacillus velezensis Strain BV379 for Human Probiotic Applications

Antibiotic susceptibility of Bacillus velezensis

Contact Info

Product

Resources

About